This company has been marked as potentially delisted and may not be actively trading. CymaBay Therapeutics (CBAY) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CBAY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period 3 Biotech Stocks With Revolutionary Pipelines to Buy TodayJuly 29, 2024 | stocknews.comVanguard Group Inc. Purchases 598,707 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)April 6, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.comApril 3, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $17.63 Million in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)March 28, 2024 | marketbeat.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 22, 2024 | za.investing.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | markets.businessinsider.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 22, 2024 | businesswire.comCymaBay Therapeutics (Nasdaq:CBAY) HeadlineTrading was temporarily halted for "CBAY" at 07:03 PM with a stated reason of "News pending."...March 22, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Sold by Deutsche Bank AGMarch 22, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Reaches New 52-Week High at $32.48March 18, 2024 | marketbeat.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 16, 2024 | finance.yahoo.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Sees Significant Drop in Short InterestMarch 14, 2024 | marketbeat.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 11, 2024 | finance.yahoo.comGlenmede Trust Co. NA Buys Shares of 37,894 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)March 10, 2024 | marketbeat.comSeven Eight Capital LP Purchases Shares of 41,556 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)March 9, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Position Lessened by Adage Capital Partners GP L.L.C.March 5, 2024 | marketbeat.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisMarch 4, 2024 | globenewswire.comCymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.35March 1, 2024 | marketbeat.com610,770 Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Acquired by MPM Bioimpact LLCMarch 1, 2024 | marketbeat.comHC Wainwright Equities Analysts Lower Earnings Estimates for CymaBay Therapeutics, Inc. (NASDAQ:CBAY)March 1, 2024 | marketbeat.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 29, 2024 | markets.businessinsider.comCymaBay Therapeutics (NASDAQ:CBAY) Rating Reiterated by HC WainwrightFebruary 29, 2024 | marketbeat.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | marketwatch.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | globenewswire.comAlgert Global LLC Purchases New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)February 28, 2024 | marketbeat.comMonashee Investment Management LLC Acquires New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)February 25, 2024 | marketbeat.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 24, 2024 | msn.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Swiss National BankFebruary 23, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stake Lessened by Deutsche Bank AGFebruary 22, 2024 | marketbeat.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | prnewswire.comLeerink Partners Downgrades CymaBay Therapeutics (CBAY)February 20, 2024 | msn.comCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2024 | globenewswire.comClariVest Asset Management LLC Sells 63,600 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)February 20, 2024 | marketbeat.comSVB Leerink Reaffirms Market Perform Rating for CymaBay Therapeutics (NASDAQ:CBAY)February 20, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Acquired by New York State Common Retirement FundFebruary 18, 2024 | marketbeat.comCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYFebruary 16, 2024 | businesswire.comFY2026 Earnings Forecast for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Issued By HC WainwrightFebruary 15, 2024 | marketbeat.comCBAY Jan 2026 37.000 callFebruary 15, 2024 | finance.yahoo.comCBAY Feb 2024 33.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Jan 2025 8.000 putFebruary 14, 2024 | finance.yahoo.comAnalysts Offer Predictions for CymaBay Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CBAY)February 14, 2024 | marketbeat.comAnalysts see over 50% gains in these 2 mid-cap biotech stocks (CBAY)The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.February 14, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Market Perform Rating from Lifesci CapitalFebruary 14, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading VolumeFebruary 13, 2024 | marketbeat.comCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver FranchiseFebruary 13, 2024 | seekingalpha.com Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBAY Media Mentions By Week CBAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CBAY News Sentiment▼0.000.72▲Average Medical News Sentiment CBAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CBAY Articles This Week▼00▲CBAY Articles Average Week Get the Latest News and Ratings for CBAY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CymaBay Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Jyong Biotech News MorphoSys News Zymeworks News MBX Biosciences News Aerovate Therapeutics News BioAge Labs News Cybin News Virios Therapeutics News OS Therapies News Eliem Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CBAY) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CymaBay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
